Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


BPAS cleared of breaking medicines advertising rules

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 264 No 7097p747
May 20, 2000 News

BPAS cleared of breaking medicines advertising rules

Emergency contraception leafletThe British Pregnancy Advisory Service (BPAS) says that it has been cleared by the Medicines Control Agency of an alleged breach of the Medicines (Advertising) Regulations 1994.BPAS leaflet
In a statement on May 12, the BPAS said that the MCA had dismissed a complaint that BPAS leaflets produced to promote its emergency contraception service broke the law by advertising prescription medicines to the public. According to the BPAS, the MCA ruled that the leaflets were designed to increase awareness of the availability of emergency contraception through services provided by the BPAS.
"The MCA does not seek to restrict access to information," it said. "The material submitted appears to be factual and health educational and is therefore not in breach of the advertising Regulations."
Ms Ann Furedi (director of communications, BPAS) said: "We were amazed that the literature was a cause of complaint. The leaflet does not promote any specific product and so cannot be said to be advertising one. It was intended to promote awareness of a useful contraceptive method and of our service."

Citation: The Pharmaceutical Journal URI: 20001539

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.